Long-term Outcomes With Ozanimod in the DAYBREAK Extension Trial by Number of MS Relapses During the Phase 3 Trials

Authors
Category Primary study
ConferenceEuropean Journal of Neurology
Year 2022
This article has no abstract
Epistemonikos ID: 8fccc562e5a8fe194e5bf4181e389e2e247a8f2d
First added on: Apr 30, 2026